The recreational drugMDMA ("ecstasy") and a variety of related drugs have been described asempathogen-entactogens, or simply asentactogens.[2] These agents possess serenic andempathy-increasing properties in addition to theireuphoriant effects, and have been associated with increased sociability, friendliness, and feelings of closeness to others as well asemotional empathy andprosocial behavior.[3][4] The entactogenic effects of these drugs are thought to be related to their ability to temporarily increase the levels of certain brain chemicals, includingserotonin,[5]dopamine, and, particularly,oxytocin.[3][6][7]
Nicotinic acetylcholine receptors within the CNS, specificallyα7 homopentameric receptors, are implicated in the regulation of aggression. The serenic effect of nicotine is well documented both in laboratory animals and humans, and, conversely,nicotinic receptor antagonists and nicotine withdrawal are associated with irritability and aggression.[36][37][38] Additionally, nicotinic receptors are required forrabies virus entry into a neuron, and the dysfunction of these neurons is implicated in the rabies-associated aggression.[39]
^Cami J, Farré M, Mas M, Roset PN, Poudevida S, Mas A, et al. (August 2000). "Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects".Journal of Clinical Psychopharmacology.20 (4):455–466.doi:10.1097/00004714-200008000-00010.PMID10917407.
^Dumont GJ, Sweep FC, van der Steen R, Hermsen R, Donders AR, Touw DJ, et al. (2009). Eslinger P, Boggio PS, Young L, Zahn R (eds.). "Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration".Social Neuroscience.4 (4).London, United Kingdom of Great Britain: Society for Social Neuroscience/Taylor & Francis:359–366.doi:10.1080/17470910802649470.LCCN2006244001.OCLC69984013.PMID19562632.S2CID12310995.
^Broadbear JH, Kabel D, Tracy L, Mak P (April 2014). Koob JF, Schulteis G, Kantak KM, Arends M, Buisman-Pijlman FT, Broadbear JH, Zoltán S (eds.). "Oxytocinergic regulation of endogenous as well as drug-induced mood".Pharmacology, Biochemistry, and Behavior.119 (1).Amsterdam, Netherlands:Elsevier:61–71.doi:10.1016/j.pbb.2013.07.002.LCCN73644949.OCLC1787728.PMID23872370.S2CID19772247.
^de Boer SF, Koolhaas JM (December 2005). Redegeld FA, Verri WA, Burk J (eds.). "5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis".European Journal of Pharmacology.526 (1–3).Amsterdam, Netherlands:Elsevier:125–139.doi:10.1016/j.ejphar.2005.09.065.LCCNsf97001017.OCLC01568459.PMID16310183.
^abcdefPopova NK, Tsybko AS, Naumenko VS (August 2022)."The Implication of 5-HT Receptor Family Members in Aggression, Depression and Suicide: Similarity and Difference".Int J Mol Sci.23 (15): 8814.doi:10.3390/ijms23158814.PMC9369404.PMID35955946.There are some pharmacological data indicating a link between aggressive behavior and 5-HT2A receptor activity. In animals, 5-HT2A agonists, such as DOI, reduced aggressive behavior in flies, amphibians, mice and rats [34]. However, accumulated data also revealed a pro-aggressive effect of the 5-HT2A agonist DOI [119,120], whereas 5-HT2A antagonists effectively suppressed aggressive behavior [119,121,122]. In humans, a number of atypical antipsychotics, which act as antagonists of 5-HT2A receptors, had antiaggressive effects in clinical trials reviewed by Comai and co-authors [123]. [...] There are a few currently available data in support of the antiaggressive role of 5-HT2C receptors: (1) the activation of 5-HT2C receptors enhanced the display of defeat submissive and defensive behavior in golden hamsters [172]. (2) 5-HT2C receptor agonist/alpha 2 receptor antagonist S32212 suppressed aggressive behavior in mice [173]. (3) Mice expressing only the VGV isoform of 5-HT2C receptors displayed a high level of conspecific aggression [174]. (4) The association between Htr2c gene polymorphism and criminal behavior in humans was demonstrated [175]. (5) Recently, a novel 5-HT2C agonist, lorcaserin, has been demonstrated to have antiaggressive properties in human subjects with impulsive aggressive behavior. Lorcaserin attenuated provoked, but not unprovoked, aggression in impulsively aggressive individuals indicating that 5-HT2C receptor may be a putative target for the treatment of impulsive aggressive behavior in human subjects [176].
^Desilva, Nilifa; Hollander, Eric (2023). "Impulse Control Disorders: Intermittent Explosive Disorder, Kleptomania, Pyromania".Tasman's Psychiatry. Cham: Springer International Publishing. p. 1–49.doi:10.1007/978-3-030-42825-9_165-1.ISBN978-3-030-42825-9.Based on evidence from a recent pilot study, lorcaserin, a selective 5-HT2c agonist, was found to have anti-aggressive effects in humans with high levels of impulsive aggression like in those diagnosed with IED.
^Tahir T, Wong MM, Maaz M, Naufal R, Tahir R, Naidoo Y (May 2022). "Pharmacotherapy of impulse control disorders: A systematic review".Psychiatry Res.311 114499.doi:10.1016/j.psychres.2022.114499.PMID35305343.
^Coccaro EF, Lee RJ (November 2019). "5-HT2c agonist, lorcaserin, reduces aggressive responding in intermittent explosive disorder: A pilot study".Hum Psychopharmacol.34 (6) e2714.doi:10.1002/hup.2714.PMID31774584.
^Morrison TR, Melloni RH (2014). "The role of serotonin, vasopressin, and serotonin/vasopressin interactions in aggressive behavior".Neuroscience of Aggression. Curr Top Behav Neurosci. Vol. 17. pp. 189–228.doi:10.1007/7854_2014_283.ISBN978-3-662-44280-7.PMID24496652.Another 5HT2A receptor partial agonist, DOB, has a marginally higher affinity for the 5HT2A receptor (in its low affinity state) than DOI (Roth et al. 1997), and in the water competition (WC) test it has been shown to block defensive aggression in rats. Interestingly, DOI also reduced the number of offensive aggressive behaviors (i.e., attacks, greater latency to first attack, shorter attack duration) in the same animals that exhibited DOI-induced reductions in defensive behaviors during the WC test (Muehlenkamp et al. 1995).
^Muehlenkamp F, Lucion A, Vogel WH (April 1995). "Effects of selective serotonergic agonists on aggressive behavior in rats".Pharmacology Biochemistry and Behavior.50 (4):671–674.doi:10.1016/0091-3057(95)00351-7.PMID7617717.S2CID12774131.
^Miczek KA, Fish EW, De Bold JF, De Almeida RM (October 2002). "Social and neural determinants of aggressive behavior: pharmacotherapeutic targets at serotonin, dopamine and gamma-aminobutyric acid systems".Psychopharmacology (Berl).163 (3–4):434–458.doi:10.1007/s00213-002-1139-6.PMID12373445.
^Sánchez C, Meier E (February 1997). "Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?".Psychopharmacology (Berl).129 (3):197–205.doi:10.1007/s002130050181.PMID9084057.
^Itil TM, Wadud A (February 1975). "Treatment of human aggression with major tranquilizers, antidepressants, and newer psychotropic drugs".J Nerv Ment Dis.160 (2–1):83–99.doi:10.1097/00005053-197502000-00003.PMID235010.
^abComai S, Tau M, Pavlovic Z, Gobbi G (April 2012). "The psychopharmacology of aggressive behavior: a translational approach: part 2: clinical studies using atypical antipsychotics, anticonvulsants, and lithium".J Clin Psychopharmacol.32 (2):237–260.doi:10.1097/JCP.0b013e31824929d6.PMID22367663.
^Guay DR (December 2007). "Newer antiepileptic drugs in the management of agitation/aggression in patients with dementia or developmental disability".Consult Pharm.22 (12):1004–1034.doi:10.4140/tcp.n.2007.1004.PMID18198960.
^abcGallagher D, Herrmann N (October 2014). "Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy?".Drugs.74 (15):1747–1755.doi:10.1007/s40265-014-0293-6.PMID25239267.
^abBoyce TG, Ballone NT, Certa KM, Becker MA (2021). "The Use of β-Adrenergic Receptor Antagonists in Psychiatry: A Review".J Acad Consult Liaison Psychiatry.62 (4):404–412.doi:10.1016/j.jaclp.2020.12.009.PMID34210401.
^Stuckelman ZD, Mulqueen JM, Ferracioli-Oda E, Cohen SC, Coughlin CG, Leckman JF, Bloch MH (June 2017). "Risk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis".J Clin Psychiatry.78 (6):e648–e655.doi:10.4088/JCP.15r10601.PMID28682529.
^O'Malley KY, Hart CL, Casey S, Downey LA (October 2022). "Methamphetamine, amphetamine, and aggression in humans: A systematic review of drug administration studies".Neurosci Biobehav Rev.141 104805.doi:10.1016/j.neubiorev.2022.104805.hdl:10072/422156.PMID35926727.
^Ferris CF, Lu SF, Messenger T, Guillon CD, Heindel N, Miller M, et al. (February 2006). Griebel G, Arends MA, Izenwasser S (eds.). "Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior".Pharmacology, Biochemistry, and Behavior.83 (2).Amsterdam, Netherlands:169–174.doi:10.1016/j.pbb.2006.01.001.OCLC67271683.PMID16504276.S2CID24199104.
^Pinna G, Agis-Balboa RC, Pibiri F, Nelson M, Guidotti A, Costa E (October 2008). Schousboe A (ed.). "Neurosteroid biosynthesis regulates sexually dimorphic fear and aggressive behavior in mice".Neurochemical Research.33 (10).Geneva, Switzerland:Springer:1990–2007.doi:10.1007/s11064-008-9718-5.PMID18473173.S2CID19338424.
^Giammanco M, Tabacchi G, Giammanco S, Di Majo D, La Guardia M (April 2005). "Testosterone and aggressiveness".Med Sci Monit.11 (4): RA136–45.PMID15795710.
^Albert DJ, Jonik RH, Walsh ML (1992). "Hormone-dependent aggression in male and female rats: experiential, hormonal, and neural foundations".Neurosci Biobehav Rev.16 (2):177–192.doi:10.1016/s0149-7634(05)80179-4.PMID1630729.